Cogent Biosciences Inc. (COGT)
$34.95
$0.38
(1.10%)
As on 03-Sep-2026 16:00EDT
Market cap
$6,016 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
13.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.3
-
Face value
--
-
Shares outstanding
173,524,982
9 Years Aggregate
CFO
$-467.64 Mln
EBITDA
$-626.80 Mln
Net Profit
$-578.32 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cogent Biosciences (COGT)
| -1.6 | -10.2 | 6.7 | 191.3 | 39.1 | 32.9 | -- |
|
BSE Sensex*
| -9.4 | -2.4 | 3.2 | -4.8 | 5.5 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cogent Biosciences (COGT)
| 355.4 | 32.3 | -49.1 | 34.7 | -23.6 | 289.8 | -83.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cogent Biosciences (COGT)
|
35.0 | 6,016.1 | 0.0 | -377.2 | -- | -64.5 | -- | 13.8 |
| 86.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 271.1 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 74.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.8 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 371.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.6 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.4 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 355.2 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Cogent Biosciences (COGT)
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase... 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts. Read more
-
President, CEO & Director
Mr. Andrew R. Robbins M.B.A.
-
President, CEO & Director
Mr. Andrew R. Robbins M.B.A.
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cogent Biosciences (COGT)
What is the current share price of Cogent Biosciences Inc (COGT) Today?
The share price of Cogent Biosciences Inc (COGT) is $34.95 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Cogent Biosciences Inc (COGT) has given a return of 39.12% in the last 3 years.
What is the current PB & PE ratio of Cogent Biosciences Inc (COGT)?
Since, TTM earnings of Cogent Biosciences Inc (COGT) is negative, P/E ratio is not available.
The P/B ratio of Cogent Biosciences Inc (COGT) is 13.76 times as on 28-Aug-2026, a 166 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-17.38 |
8.99 |
2024 |
-3.37 |
3.36 |
2023 |
-2.65 |
1.98 |
2022 |
-6.14 |
3.19 |
2021 |
-5.20 |
1.75 |
What is the 52 Week High and Low of Cogent Biosciences Inc (COGT)?
The 52-week high and low of Cogent Biosciences Inc (COGT) are Rs 43.73 and Rs 11.60 as of 04-Sep-2026.
What is the market cap of Cogent Biosciences Inc (COGT)?
Cogent Biosciences Inc (COGT) has a market capitalisation of $ 6,016 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cogent Biosciences Inc (COGT)?
Before investing in Cogent Biosciences Inc (COGT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.